US-based pharma giant Eli Lilly’s blockbuster weight-loss drug, Mounjaro, is set to expand its reach across India through a partnership with Mumbai-based Indian pharma major Cipla.
The weekly injectable will be marketed under a new brand name, Yurpeak, leveraging Cipla’s extensive distribution network to reach consumers beyond major cities.
Mounjaro, which contains tirzepatide as its active pharmaceutical ingredient (API), was launched in India on March 20 this year—three months before its Danish rival Novo Nordisk introduced Wegovy with semaglutide as its API.
advertisement
Within six months of its debut, Mounjaro became the second-highest-selling drug in India, recording sales worth 80 crore in September, according to data from marketing intelligence and analytics firm Pharmarack.
On October 23, Lilly and Mumbai-based Cipla announced a joint agreement to distribute and promote tirzepatide under t
Continue Reading on India Today
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.